245 filings
Page 3 of 13
DEFA14A
1wn3pm
20 Apr 21
Additional proxy soliciting materials
4:28pm
8-K
coa 7be6krbgc0
12 Apr 21
Entry into a Material Definitive Agreement
5:16pm
8-K
rb9 5czyo
12 Mar 21
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
3advgkjwejlr4
2 Mar 21
Regulation FD Disclosure
7:30am
S-8
bf34eb8x
26 Feb 21
Registration of securities for employees
6:54am
8-K
xlfd4ey91glrb hym
25 Feb 21
Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update
4:14pm
8-K
hmuicvss qy6v1kv
12 Jan 21
Results of Operations and Financial Condition
8:00am
8-K
6yy24u6l els3ae5i6xi
5 Nov 20
Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update
4:14pm
8-K
hvs5sf
22 Oct 20
Other Events
4:18pm
8-K
gcemlie1
16 Sep 20
Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary
7:39am
8-K
gcv0jxx4o04hms7c
14 Sep 20
Regulation FD Disclosure
7:53am
8-K
llla9
13 Aug 20
Regulation FD Disclosure
12:00am
8-K/A
z1umds fp08cp1d5
11 Aug 20
Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update
8:25am
8-K
u8b7n1nazc1b9ay
6 Aug 20
Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update
7:05am
8-K
9vqazf1vf19wd0zh527
8 Jul 20
Entry into a Material Definitive Agreement
5:12pm
8-K
8d00e
18 Jun 20
Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria
7:32am